• PDF / 166,489 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 46 Downloads / 205 Views

DOWNLOAD

REPORT

1173-5503/20/0860-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 22 Aug 2020 No. 860

1

Recommend Documents

Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transpl

135 97 647KB

Anti-neutrophil Cytoplasmic Antibodies in New-onset Systemic Lupus Erythematosus and Lupus Nephritis

179 107 128KB

Genetic variants of microRNA-146a gene: an indicator of systemic lupus erythematosus susceptibility, lupus nephritis, an

162 99 553KB

ICER

138 90 57MB

Preclinical Testing of Viral Therapeutic Efficacy in Pristane-Induced Lupus Nephritis and Diffuse Alveolar Hemorrhage Mo

121 116 8MB

ICER favours vinorelbine + cisplatin for NSCLC

180 102 120KB

Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis

150 19 829KB

Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide

142 99 135KB

Steroid treatment promotes an M2 anti-inflammatory macrophage phenotype in childhood lupus nephritis

144 31 2MB

Belimumab/glucocorticoids/rituximab

143 80 165KB

Value of monitoring urine ammonia at time of biopsy in patients with lupus nephritis

137 29 597KB

ICER news September 2020

184 70 171KB